Genentech’s Rituxan approved for rare skin disease
autoimmune disease, FDA approval, Genentech, pemphigus vulgaris, PV, rare disease, Rituxan, Roche
0 Comment
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.